NCT00212888 is a Phase 1/Phase 2 clinical trial of Remune and ALVAC in HIV Infections, sponsored by Ottawa Hospital Research Institute.

Who is sponsoring NCT00212888?

NCT00212888 is sponsored by Ottawa Hospital Research Institute.

What drugs are being tested in NCT00212888?

Interventions in NCT00212888: Remune and ALVAC.

What condition does NCT00212888 study?

NCT00212888 studies HIV Infections.

Is NCT00212888 still recruiting?

NCT00212888 is currently completed. Last updated 19 March 2019.

Are results published for NCT00212888?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-03-19 · How we verify

NCT00212888

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression

Completed Phase 1/Phase 2 Results posted Last updated 19 March 2019

What this trial tests

Phase 1/Phase 2 trial testing Remune and ALVAC in HIV Infections in 52 participants. Completed in 1 November 2010.

Timeline

1 April 2004

Primary endpoint
1 July 2010

1 November 2010

Quick facts

Lead sponsor	Ottawa Hospital Research Institute
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	triple
Primary purpose	treatment
Enrollment	52
Start date	1 April 2004
Primary completion	1 July 2010
Estimated completion	1 November 2010
Sites	3 locations across Canada

Drugs / interventions tested

Remune and ALVAC — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Ottawa Hospital Research Institute

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group
Time frame: Up to week 48

Sponsor's own description

The purpose of this study is to determine if vaccination before a structured treatment interruption (STI) is associated with an improvement in immune function, resulting in a delayed and reduced rebound in the amount of HIV virus in the blood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Ottawa Hospital Research Institute trials

Trials by the same sponsor.

NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00212888 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
Last refreshed: 19 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00212888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing